NovaBay Pharmaceuticals Inc. (NBY)

1.15
0.07 6.33
AMEX : Health Technology
Prev Close 1.08
Open 1.05
Day Low/High 1.05 / 1.22
52 Wk Low/High 0.23 / 4.04
Volume 546.92K
Avg Volume 2.57M
Exchange AMEX
Shares Outstanding 19.17M
Market Cap 24.16M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

NovaBay Pharmaceuticals Raises $2.4 Million In A Private Placement

NovaBay Pharmaceuticals Raises $2.4 Million In A Private Placement

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, announces the closing of a private placement of common stock and warrants with accredited investors,...

NovaBay Pharmaceuticals Appoints Justin Hall President And CEO, And Jason Raleigh CFO

NovaBay Pharmaceuticals Appoints Justin Hall President And CEO, And Jason Raleigh CFO

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, announces the appointments of Justin Hall as President and Chief Executive Officer, and Jason Raleigh...

NovaBay Pharmaceuticals Launches Avenova® Direct On Amazon.com

NovaBay Pharmaceuticals Launches Avenova® Direct On Amazon.com

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, announces that Avenova ® Direct is available at affordable pricing and without a prescription on...

NovaBay Pharmaceuticals Receives NYSE American Communication

NovaBay Pharmaceuticals Receives NYSE American Communication

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, announces that on May 16, 2019 it received notice (the "Notice") from the NYSE American...

NovaBay Pharmaceuticals Reports First Quarter 2019 Financial Results

NovaBay Pharmaceuticals Reports First Quarter 2019 Financial Results

NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, reports financial results for the three months ended March 31, 2019 and provides a...

NovaBay Pharmaceuticals To Hold First Quarter 2019 Conference Call On May 9, 2019

NovaBay Pharmaceuticals To Hold First Quarter 2019 Conference Call On May 9, 2019

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, announces that it will report first quarter 2019 financial results after market close on...

NovaBay Pharmaceuticals Announces Annual Meeting Of Stockholders And Receives NYSE American Communication

NovaBay Pharmaceuticals Announces Annual Meeting Of Stockholders And Receives NYSE American Communication

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, announces that it will hold a virtual Annual Meeting of Stockholders on Thursday, May 30,...

NovaBay Pharmaceuticals Announces New Partner Pharmacy Program

NovaBay Pharmaceuticals Announces New Partner Pharmacy Program

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company, announces a new pharmacy partnering program in a continued effort to ensure all patients in the U.

NovaBay Pharmaceuticals Announces Investments Of $5 Million To Support U.S. Avenova Commercialization Strategy

NovaBay Pharmaceuticals Announces Investments Of $5 Million To Support U.S. Avenova Commercialization Strategy

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, announces investments totaling $5 million to support the recent strategic shift in its U.

NovaBay Pharmaceuticals Reports 2018 Fourth Quarter And Full Year Financial Results

NovaBay Pharmaceuticals Reports 2018 Fourth Quarter And Full Year Financial Results

NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, reports financial results for the three and 12 months ended December 31, 2018 and...

NovaBay Pharmaceuticals Announces Strategic Shift In U.S. Avenova Commercialization Strategy

NovaBay Pharmaceuticals Announces Strategic Shift In U.S. Avenova Commercialization Strategy

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, announces a strategic shift in its U.

NovaBay Pharmaceuticals Announces Preliminary 2018 Net Sales And Introduces 2019 Net Sales Guidance

NovaBay Pharmaceuticals Announces Preliminary 2018 Net Sales And Introduces 2019 Net Sales Guidance

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, announces 2018 net sales are expected to be $12.

NovaBay Pharmaceuticals Reports Third Quarter 2018 Financial Results

NovaBay Pharmaceuticals Reports Third Quarter 2018 Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, reports financial results for the three and nine months ended September 30, 2018 and...

NovaBay Pharmaceuticals To Hold Third Quarter 2018 Conference Call On November 14, 2018

NovaBay Pharmaceuticals To Hold Third Quarter 2018 Conference Call On November 14, 2018

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, announces that it will report third quarter 2018 financial results after market close on...

NovaBay Pharmaceuticals Names Jack McGovern Interim CEO

NovaBay Pharmaceuticals Names Jack McGovern Interim CEO

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, announces that Jack McGovern has been named Interim Chief Executive Officer, expanding...

NovaBay Pharmaceuticals To Present At H.C. Wainwright 20th Annual Global Investment Conference On September 6

NovaBay Pharmaceuticals To Present At H.C. Wainwright 20th Annual Global Investment Conference On September 6

NovaBay ® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, announces that management is scheduled to present a corporate overview at the H.

NovaBay Pharmaceuticals Reports Second Quarter 2018 Financial Results

NovaBay Pharmaceuticals Reports Second Quarter 2018 Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, reports financial results for the three and six months ended June 30, 2018 and provides a...

NovaBay Pharmaceuticals To Hold Second Quarter 2018 Conference Call On August 7, 2018

NovaBay Pharmaceuticals To Hold Second Quarter 2018 Conference Call On August 7, 2018

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, announces that it will report second quarter 2018 financial results after market close on...

NovaBay Pharmaceuticals Expands Sales Organization To Re-energize Growth

NovaBay Pharmaceuticals Expands Sales Organization To Re-energize Growth

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, announces it has completed the most recent planned expansion of its salesforce by hiring...

NovaBay Pharmaceuticals Reports First Quarter 2018 Financial Results

NovaBay Pharmaceuticals Reports First Quarter 2018 Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, reports financial results for the three months ended March 31, 2018 and provides a...

NovaBay Pharmaceuticals To Hold First Quarter 2018 Conference Call On May 10, 2018

NovaBay Pharmaceuticals To Hold First Quarter 2018 Conference Call On May 10, 2018

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report first quarter 2018...

NovaBay Pharmaceuticals Reports 2017 Fourth Quarter And Full Year Financial Results

NovaBay Pharmaceuticals Reports 2017 Fourth Quarter And Full Year Financial Results

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, reports financial results for the three...

NovaBay Pharmaceuticals To Hold 2017 Fourth Quarter And Full Year Conference Call On March 20, 2018

NovaBay Pharmaceuticals To Hold 2017 Fourth Quarter And Full Year Conference Call On March 20, 2018

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova ® lid and lash hygiene product for the domestic eye care market, announces...

NovaBay Pharmaceuticals Completes $6.0 Million Private Placement

NovaBay Pharmaceuticals Completes $6.0 Million Private Placement

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focused on commercializing Avenova ®, a prescription product for the domestic eye care market, announces the completion of a...

NovaBay Pharmaceuticals Announces Preliminary Sales For 2017 Fourth Quarter And Full Year

NovaBay Pharmaceuticals Announces Preliminary Sales For 2017 Fourth Quarter And Full Year

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® lid and lash hygiene for the domestic eye care market, announces that...

NovaBay Pharmaceuticals Receives Stockholder Approval For Proposed $10.32 Million Financing Agreement

NovaBay Pharmaceuticals Receives Stockholder Approval For Proposed $10.32 Million Financing Agreement

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for the domestic eye care market, announces stockholder approval to issue...

NovaBay Pharmaceuticals Regains Compliance With NYSE American Continued Listing Standards

NovaBay Pharmaceuticals Regains Compliance With NYSE American Continued Listing Standards

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova lid and lash hygiene for the domestic eye care market, announces that it has...

NovaBay Pharmaceuticals Names Lewis J. Stuart Chief Commercial Officer

NovaBay Pharmaceuticals Names Lewis J. Stuart Chief Commercial Officer

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova ® for lid and lash hygiene in the domestic eye care market, announces the...

TheStreet Quant Rating: D (Sell)